Presbyopia

Vizz (LENZ Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution to correct vision for up to 10 hours.

Marc Bloomenstein, OD, FAAO, is a clinical investigator in the trials and overviews the transformative potential of LNZ100.

Beginning in July 21, the Varilux Physio extensee and Varilux Physio extensee Classic Edition will be available in the US.

The Innovation Hub was split into 3 panel discussions on assessing future health through AI-enabled tools, addressing patient workflow challenges through AI, and enhancing treatment through new technologies.

The PDUFA date for Brimochol PF is January 28, 2026.

Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.

Digital Twin and VESA can integrate refractive data, topography, biomechanical properties, and even simulate age-related changes in the eye—turning it into a predictive and diagnostic tool for clinicians managing complex conditions like presbyopia.

Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO, provided their insights during CIME 2025 on May 4.

Selina McGee, OD, FAAO, emphasized that today’s approach to presbyopia correction must move beyond traditional methods like spectacles and contact lenses.

While the study included a range of patients in a variety of stages of presbyopia, the change in crystalline lens and anterior segment geometry was most pronounced in emmetropic and myopic presbyopes.

At ASCRS 2025, Alex Hacopian, MD, shares information from his presentation on next-gen presbyopia-correcting intraocular lenses.

Brimochol PF’s combination of brimonidine and carbachol produces a “pinhole effect,” which is intended to improve depth of focus and sharpen near and distant impact.

The lens has been introduced to select practices across the US, with broad commercial availability planned for in May.

The novel corrective eye drop can be prescribed through pharmacy partners BlinkRx or Medvantx.

The new lenses are designed for young presbyopes, ranging in age from their late 30s to mid-40s, who may be either existing spectacle wearers or non-wearers.

Understanding the precise formulation of pharmacologic agents for refractive correction for presbyopia.

Cecelia Koetting, OD, FAAO, DipABO, and Madeline Yung, MD, discussed emerging treatment and patient care options for those with presbyopia during CRU 2025.

The 6th World Congress of Optometry will be held during Saudi Society of Optometry’s 11th Optometry Conference and Exhibition.

Updates include enrollments for LYNX-2 pivotal Phase 3 and VEGA-3 pivotal Phase 3 trials, in addition to a US FDA Fast Track Designation granted for phentolamine 0.75% for the treatment of significant chronic night driving impairment in keratorefractive patients with reduced mesopic vision.

Attention to patients' near visual needs is warranted when choosing medications.

Two posters presented research conducted on the optical design used in MyDay Energys and Biofinity Energys.

The 3-arm, multicenter, randomized, double masked, safety and efficacy study successfully met pre-specified visual acuity primary endpoints with statistically significant near vision improvements recorded at all time points over 8 hours.

74% of participants dosed with LNZ100 achieved 3 or more lines of improvement 3 hours post-treatment.